Eli Lilly shares soar 13% on Alzheimer’s drug trial results

Pharma company's experimental Alzheimer’s drug Donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease

Eli Lilly in Eastgate, Cork.     

Shares in Eli Lilly soared 13% as a trial of its experimental Alzheimer’s drug Donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease.

The drug is an antibody designed to remove clumps of the Alzheimer’s-related protein beta amyloid from the brain.